다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Gain Therapeutics Inc (GANX)
Gain Therapeutics Inc (GANX) 뉴스

GANX

Gain Therapeutics (GANX)

Gain Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:GANX

1 2 3 4 5 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/15	05:06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:GANX	Gain Therapeutics Inc
2024/05/15	05:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GANX	Gain Therapeutics Inc
2024/05/14	20:30	GlobeNewswire Inc.	Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update	NASDAQ:GANX	Gain Therapeutics Inc
2024/04/24	22:25	GlobeNewswire Inc.	Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease	NASDAQ:GANX	Gain Therapeutics Inc
2024/04/08	22:25	GlobeNewswire Inc.	Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer	NASDAQ:GANX	Gain Therapeutics Inc
2024/04/01	22:25	GlobeNewswire Inc.	Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer	NASDAQ:GANX	Gain Therapeutics Inc
2024/03/26	21:00	GlobeNewswire Inc.	Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update	NASDAQ:GANX	Gain Therapeutics Inc
2024/03/16	03:30	GlobeNewswire Inc.	Gain Therapeutics to Present at Public Ventures Discovery Day	NASDAQ:GANX	Gain Therapeutics Inc
2024/03/05	22:00	GlobeNewswire Inc.	Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease	NASDAQ:GANX	Gain Therapeutics Inc
2024/02/28	04:00	GlobeNewswire Inc.	Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease	NASDAQ:GANX	Gain Therapeutics Inc
2024/02/22	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GANX	Gain Therapeutics Inc
2024/02/15	02:29	GlobeNewswire Inc.	Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight	NASDAQ:GANX	Gain Therapeutics Inc
2024/02/06	23:56	GlobeNewswire Inc.	UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease	NASDAQ:GANX	Gain Therapeutics Inc
2024/02/06	22:00	GlobeNewswire Inc.	Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease	NASDAQ:GANX	Gain Therapeutics Inc
2024/02/01	07:26	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GANX	Gain Therapeutics Inc
2024/01/31	22:00	GlobeNewswire Inc.	Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update	NASDAQ:GANX	Gain Therapeutics Inc
2024/01/03	06:09	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:GANX	Gain Therapeutics Inc
2024/01/02	22:00	GlobeNewswire Inc.	Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024	NASDAQ:GANX	Gain Therapeutics Inc
2024/01/02	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:GANX	Gain Therapeutics Inc
2023/12/20	06:52	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:GANX	Gain Therapeutics Inc
2023/12/01	22:00	GlobeNewswire Inc.	Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/29	22:00	GlobeNewswire Inc.	Gain Therapeutics to Participate in AI Driven Drug Discovery Summit	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/25	03:01	GlobeNewswire Inc.	Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/24	20:07	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/23	07:27	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/21	22:54	GlobeNewswire Inc.	Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/21	06:22	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/21	06:03	GlobeNewswire Inc.	Gain Therapeutics Announces Proposed Public Offering	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/18	06:27	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/15	06:05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:GANX	Gain Therapeutics Inc

검색 관련기사 보기:NASDAQ:GANX

1 2 3 4 5 다음 >>

Scotch Creek Ventures

Barclays Bank PLC

John Hancock Hedged Equi...

Ivz Jpn Esg Acc

PETRJ359 Ex:33,12

iShares MSCI Emerging Ma...

Isis Property Trust

BeachHead Dollar

Sonics and Materials (CE)

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관